collection
https://read.qxmd.com/read/31651132/the-prevalence-and-management-of-metabolic-acidosis-of-chronic-kidney-disease
#1
JOURNAL ARTICLE
A R Ahmed, M M Satti, A E Abdalla, L Giblin, D Lappin
Aim Emerging evidence supports initiating oral sodium bicarbonate (OSB) at a serum bicarbonate (HCO3) level of less than 22mmol/L. We look to identify the prevalence of metabolic acidosis of chronic kidney disease (MA-CKD) and its management with OSB at a regional university hospital. Methods Retrospective data was collected using the national electronic renal database (eMED) to identify chronic kidney disease (CKD) patients with MA-CKD over a one-year period. Results One-hundred and forty-four patients were identified with CKD, of which 131 (89%) were tested for HCO3...
October 15, 2019: Irish Medical Journal
https://read.qxmd.com/read/30524708/the-potential-for-improving-cardio-renal-outcomes-by-sodium-glucose-co-transporter-2-inhibition-in-people-with-chronic-kidney-disease-a-rationale-for-the-empa-kidney-study
#2
REVIEW
William G Herrington, David Preiss, Richard Haynes, Maximilian von Eynatten, Natalie Staplin, Sibylle J Hauske, Jyothis T George, Jennifer B Green, Martin J Landray, Colin Baigent, Christoph Wanner
Diabetes is a common cause of chronic kidney disease (CKD), but in aggregate, non-diabetic diseases account for a higher proportion of cases of CKD than diabetes in many parts of the world. Inhibition of the renin-angiotensin system reduces the risk of kidney disease progression and treatments that lower blood pressure (BP) or low-density lipoprotein cholesterol reduce cardiovascular (CV) risk in this population. Nevertheless, despite such interventions, considerable risks for kidney and CV complications remain...
December 2018: Clinical Kidney Journal
https://read.qxmd.com/read/30392544/glucose-lowering-therapies-for-cardiovascular-risk-reduction-in-type-2-diabetes-mellitus-state-of-the-art-review
#3
REVIEW
Salvatore Carbone, Dave L Dixon, Leo F Buckley, Antonio Abbate
Type 2 diabetes mellitus (T2DM) is a major cardiovascular (CV) risk factor. Although antihyperglycemic therapies have typically focused on glycemic control, a paradigm shift for the treatment of T2DM has occurred, with an increased focus on CV risk reduction. Clinicians should base their clinical decisions on the beneficial effects of specific glucose-lowering agents on CV outcomes, while avoiding those therapeutic strategies with potential detrimental effects. Importantly, the presence of comorbidities (eg, established cardiovascular diseases, hypertension, obesity) should also guide the clinical decision toward therapies proven to reduce CV outcomes in that specific population...
November 2018: Mayo Clinic Proceedings
https://read.qxmd.com/read/30132304/phosphate-binders-for-preventing-and-treating-chronic-kidney-disease-mineral-and-bone-disorder-ckd-mbd
#4
JOURNAL ARTICLE
Marinella Ruospo, Suetonia C Palmer, Patrizia Natale, Jonathan C Craig, Mariacristina Vecchio, Grahame J Elder, Giovanni Fm Strippoli
BACKGROUND: Phosphate binders are used to reduce positive phosphate balance and to lower serum phosphate levels for people with chronic kidney disease (CKD) with the aim to prevent progression of chronic kidney disease-mineral and bone disorder (CKD-MBD). This is an update of a review first published in 2011. OBJECTIVES: The aim of this review was to assess the benefits and harms of phosphate binders for people with CKD with particular reference to relevant biochemical end-points, musculoskeletal and cardiovascular morbidity, hospitalisation, and death...
August 22, 2018: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/30132035/sglt2-inhibitors-the-future-for-treatment-of-type-2-diabetes-mellitus-and-other-chronic-diseases
#5
REVIEW
Christoph Wanner, Nikolaus Marx
Individuals with diabetes mellitus exhibit an increased propensity to develop cardiovascular disorders such as coronary artery disease, stroke and heart failure. Over recent decades, numerous cardiovascular outcome trials in individuals with type 2 diabetes have been published, with data showing a reduction of cardiovascular morbidity and mortality by sodium-glucose cotransporter 2 (SGLT2) inhibitors. These results not only provide novel therapeutic options for this high-risk population but also advance our current understanding of cardiovascular risk reduction in diabetes...
October 2018: Diabetologia
https://read.qxmd.com/read/21482743/a-predictive-model-for-progression-of-chronic-kidney-disease-to-kidney-failure
#6
JOURNAL ARTICLE
Navdeep Tangri, Lesley A Stevens, John Griffith, Hocine Tighiouart, Ognjenka Djurdjev, David Naimark, Adeera Levin, Andrew S Levey
CONTEXT: Chronic kidney disease (CKD) is common. Kidney disease severity can be classified by estimated glomerular filtration rate (GFR) and albuminuria, but more accurate information regarding risk for progression to kidney failure is required for clinical decisions about testing, treatment, and referral. OBJECTIVE: To develop and validate predictive models for progression of CKD. DESIGN, SETTING, AND PARTICIPANTS: Development and validation of prediction models using demographic, clinical, and laboratory data from 2 independent Canadian cohorts of patients with CKD stages 3 to 5 (estimated GFR, 10-59 mL/min/1...
April 20, 2011: JAMA
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.